St. Jude Medical Gains CE Mark for 27mm & 29mm Portico TAVR Valves to Complete a Full Portfolio of Portico Sizing Options for Physicians Treating Patients with Aortic Stenosis
The latest approval increases patient access to the Portico system, a
TAVR valve that provides excellent patient outcomes and the opportunity to
optimize device placement
ST. PAUL, Minn., St. Jude Medical, Inc.,
a global medical device company, today announced the European CE Mark approval
for the 27mm and 29mm Portico™ Transcatheter Aortic Valve Replacement System.
The approval follows previous approvals of the 23mm and 25mm Portico valves,
allowing
Aortic stenosis is one of the most common forms of cardiovascular disease in the world, and develops as the aortic heart valve becomes calcified, narrowing the valve and preventing a complete opening. Over time, aortic stenosis disrupts the blood flow from the heart, which causes the heart to pump harder and results in weakening. TAVR procedures provide physicians an additional treatment option for patients with severe aortic stenosis who are considered high risk for open heart surgery.
“Aortic stenosis is a serious, potentially life-threatening
condition for patients who are unable to receive a traditional open-heart valve
transplant,” said Dr.
The Portico system was developed to simplify TAVR procedures for physicians by improving control, ease of use and accuracy over other commercially-available TAVR valves. The system offers the ability for the Portico valve to be fully recaptured and repositioned prior to full deployment and release from the delivery system, providing physicians more options to place the valve in the targeted location. The Portico system has also demonstrated low rates of permanent pacemaker utilizations post valve implant as a result of heart block and was designed to minimize the risk of paravalvular leak (a leakage of blood caused by a space between the heart tissue and a replacement valve).
“Transcatheter aortic valve replacement is a complex
procedure, and feedback from physicians worldwide has continued to press upon
us the fact that offering a system that provides physicians more control and a
simplified procedure is important,” said
During a transfemoral implant procedure, the Portico valve is delivered by catheter through the femoral artery in the leg and is positioned while the patient’s heart continues to beat. Use of the Portico valve alleviates the use of cardiopulmonary bypass, which involves a machine taking over a patient’s heart and lung function during surgery and can cause added strain on an already frail heart.
The 23mm the 25mm Portico Transcatheter Aortic Heart Valve
are both CE Mark approved and commercially available in
Source: St. Jude Medical
Comments